Pharming vs Zai Lab
PHAR and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PHAR and ZLAB compare
Pharming grew revenue faster over the last twelve months (26.6% versus 0.02% for Zai Lab).
Pharming keeps more of each dollar of sales as profit, with a net margin of 0.76% compared with −44.9% at Zai Lab.
Pharming scores higher on the StockData Score (8 against 6 for Zai Lab), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PHAR | ZLAB |
|---|---|---|
| Size and price | ||
| Market cap | – | $41.0B |
| Share price | $13.40 | $26.42 |
| Change, 1 year | −23.6% | 20.7% |
| Change, 5 years | 55.5% | −68.6% |
| Beta (5Y) | 0.56 | 1.11 |
| Employees | 50K | 1,784 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 92.9× |
| P/B | – | 72.8× |
| FCF yield | – | −0.40% |
| Fair value | – | $4.31 |
| Margin of safety | – | −513% |
| Growth | ||
| Revenue growth (TTM) | 26.6% (better) | 0.02% |
| Revenue growth, 5Y average | 12.1% | 56.5% (better) |
| EPS growth, 5Y average | −40.8% | – |
| Profitability | ||
| Gross margin | 87.9% (better) | 54.7% |
| Operating margin | 6.9% (better) | −63.0% |
| Net margin | 0.76% (better) | −44.9% |
| FCF margin | 14.3% (better) | −37.0% |
| Return on equity | – | −30.0% |
| Return on invested capital | – | −87.6% |
| Financial health | ||
| Debt / equity | – | 0.45 |
| Interest coverage | 132× (better) | −45.2× |
| Current ratio | 2.59 (better) | 2.04 |
| Altman Z-score | – | 49.70 |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.32% | 2.8% |
| Held by insiders | 0.00% | 0.67% |
| Insider net buying, 12 months | – | −$10.8M |
Go deeper
- PHAR stock overview
- PHAR income statement
- PHAR valuation and score
- ZLAB stock overview
- ZLAB income statement
- ZLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.